We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalABMD - Replacement Heart System

Previous 10 Next 10 
From: Lynn4/4/2018 4:08:49 PM
   of 147
Abiomed Receives FDA Approval for Impella CP® with SmartAssist™ and Optical Sensor

Share RecommendKeepReplyMark as Last Read

From: Lynn4/6/2018 3:41:40 PM
   of 147
ABMD is one of the top 10 in which at least $100 million was invested as new buys by mutual funds:

New Buys By Best Mutual Funds: From Adobe To Zebra, Who Makes The List?

Share RecommendKeepReplyMark as Last Read

From: Lynn4/13/2018 2:50:41 PM
   of 147
DANVERS, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. ( NASDAQ:ABMD) announced that on Thursday, May 3, 2018, the Company will release financial results for the fourth quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, May 3, 2018, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Vice President and Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. ET May 3, 2018 through 11:00 a.m. ET on May 10, 2018. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 448 8806. [snip to end]

Share RecommendKeepReplyMark as Last Read

From: Lynn5/9/2018 6:13:27 PM
1 Recommendation   of 147
Abiomed Climbs to Record After Fiscal Q4 EPS, Rervenue Beat Analyst Estimates 12:26 PM ET, 05/03/2018 - MT Newswires12:26 PM EDT, 05/03/2018 (MT Newswires) -- Abiomed (ABMD) shares rose 11% to a record after reporting fiscal Q4 EPS of $0.80 compared with $0.33 a year earlier, beating the $0.66 average estimate of analysts in a Capital IQ poll.

The new 52-week range is $123.60 to $338.69.

Revenue was $174.4 million, an increase of 40% from $124.7 million a year earlier. That exceeded the $164.3 million analyst consensus.

The company sees total revenue in the 2019 fiscal year to be in the range of $740 million to $770 million, an increase of 25% to 30% over the previous fiscal year. It sees GAAP operating margin in the range of 28% to 30%.

Closing price: 358.16 Change +10.78 (+3.1%)

Share RecommendKeepReplyMark as Last Read

From: Lynn5/29/2018 2:09:05 PM
   of 147
ABIOMED Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Share RecommendKeepReplyMark as Last Read

From: Lynn6/2/2018 10:04:37 PM
1 Recommendation   of 147
Abiomed's Shares Doubled. What Happens Next? The size of this medical device company's market might surprise you.

Motley Fool Staff

Jun 1, 2018 at 9:00AM

Open-heart surgery in patients that have suffered major cardiovascular events is risky, but it could be getting less so thanks to temporary heart pumps sold by Abiomed ( NASDAQ:ABMD), a $17 billion market-cap medical devices company. Is Abiomed a stock worth including in your portfolio?

In this clip from Industry Focus: Healthcare, analyst Kristine Harjes and Motley Fool contributor Todd Campbell discuss why Abiomed's shares have doubled this year and what investors should know about this company's market opportunity.

A full transcript follows the video recorded on 30 May 2018 [which I have not included--click the URL at the bottom to watch the video].

Kristine Harjes: Today, we're going to talk about Abiomed, which is a $17 billion market cap company whose stock has doubled since just January of this year. Both of these companies, Loxo Oncology in the front half of the show, and now Abiomed, have been very, very high performers, but they're both kind of under the radar.

Abiomed's flagship product line is the Impella heart pump, which is the world's smallest heart pump. Revenue has been growing very swiftly with seemingly no end in sight. Todd, what's your take on Abiomed?

Todd Campbell: I'm so excited to be talking about this stock. It's kind of funny, right, when you think about it. We oftentimes tend to expect the biggest returns coming from the biopharma area, not from the medical device area. When you see that return year-to-date, it's like, what?! [laughs] Double my money in a few months in this company? Especially for a company as big as this, right? $17 billion market cap! So, you have to ask yourself, what's the excitement here? What's the reason for excitement at Abiomed? And, what's the potential for this company to continue to grow and deliver for investors?

I think that you did a great job setting the stage here to understand that what they're doing is, through medical devices, they're attacking a very, very big need for devices that can help relieve the stress that gets put on the heart following a heart attack. If you're able to relieve the heart from that stress of pumping on its own, either prior to or during surgery, or in the hours and potentially the days following that surgery, then you can get better outcomes. You can have less of a risk of complications, less of a risk of a readmittance back to the hospital after they've been sent home, and less time overall spent within the hospital, which theoretically can save payers some money there, too.

So, really, what we're talking about is the Impella heart pumps. Those are used temporarily from hours to a few days. They're used in patients who are at a critical risk -- they've had a heart attack and they're also in shock.

Harjes: Yeah, absolutely. This is a very, very large market. Heart disease, as many of our listeners will know, is the leading cause of death in the United States. It kills 875,000 people per year. It costs our healthcare system $555 billion, which is estimated to grow to $1.1 trillion annually by 2035. In that same year, 2035, it's estimated that 45% of the United States population will have heart disease, which is just a frightening and insane statistic.

Abiomed is estimating that about 221,000 U.S. patients per year would benefit from procedures using their Impella product. Despite seeing double-digit growth for revenue for quite a while, they still have a pretty long runway. They're just getting started. They don't seem to have any substantial competitors. They have that first-mover advantage. It looks like it could be early days for this company.

Campbell: Fiscal year 2017, their sales grew 35% to $445 million. In fiscal year 2018, their sales grew, again, by 33%, to $594 million. I think what got people really excited was the fact that that was better than the guidance. The guidance was for 31% growth, $582 million.

The other thing that investors should know is that this has been a profitable company since 2012. They're making money. They had $90 million in operating income in fiscal 2017, and then, that jumped in fiscal 2018, just finished up, to $157 million. So, up 74%. Your operating income grew at a much faster rate than your revenue growth, which suggests to me that as these devices are getting used more frequently, they're able to leverage their fixed costs and really accelerate their profitability for investors. Maybe that's one of the reasons that the company is debt free and its cash stockpile has been growing for three consecutive years.

Harjes: Yeah. The stats that I mentioned were U.S. stats, but they're not even just based in the United States. They're also in Europe, they have approvals there. They launched in Japan in September. They have a presence in Germany. And even though expansion is kind of slow -- and management routinely reminds investors that it has to be slow in order to ensure good outcomes, because you need to be trained to use these pumps, it's not something that you can just drop off and go away -- they have the entire world out there that they're just starting to reach. And when you think about the demographic trends in general across the entire globe of an aging population, I've said it so many times already just in this one segment, but they really do seem like they have a huge runway ahead of them.

Campbell: Well, just to put that into context, in the fiscal fourth quarter, the one that just wrapped up, their overseas sales, their ex-U.S. sales, were only $22 million. So, a very small proportion of their total sales is coming from the international markets right now. And, by the way, that was up 107% year over year, and it was really tied to one country: Germany. So, as Japan starts to accelerate, as other countries start to get more interested in the opportunity to use Impella, I think that, yeah, you could see sales grow substantially. The company, Kristine, estimates this is a $5 billion market opportunity, and they say that they're only about 9% penetrated into it.

Harjes: Yep. And the other thing that's important to realize about the business model is that there's recurring revenue. Their hospital reorder rate stands at over 90%. So, it's sticky. Once you're trained on using these, you're probably not going to move to a competitor. I saw on the Premium side of things in our Supernova service, an analyst compared this company to Intuitive Surgical, which is the robotic surgery giant. She pointed out that there were similarities in the business model, where you have that recurring revenue, there's a product that will become the standard of care, there's a long growth runway, and really solid financials. I like that comparison a lot.

I think one more thing to add to the list of why these two companies are fairly similar is a nosebleed valuation. This company is definitely not cheap, they're trading at about 30X the last 12 months of sales. Their P/E is several hundred, and that's TTM. It's not even that much better when you look on a forward basis. But, like you said, they have a very strong balance sheet. They've been profitable since fiscal 2012. So, I see a lot of similarity with Intuitive.

Campbell: Yeah. Value investors are not going to be tucking this in a portfolio, similar to what we were talking about last week on the diabetes show. These things are richly valued. But, that's not necessarily a reason to not have a stock like this in your portfolio. You need to take that valuation in the context of where the company's sales could be in five or ten years. You have to take that longer-term look and say, if they're only 9% penetrated into this massive market now, can they grow into that valuation? I'll let someone smarter than me make the answer to that. But, I'm very, very excited by the opportunity to really improve a lot of people's lives. This is a medical device that can save lives. That makes the potential for it to be a must-use device in hospitals, not a nice-to-have device.

Kristine Harjes has no position in any of the stocks mentioned. Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. Motley Fool owns shares of and recommends Abiomed and ISRG. The Motley Fool has a disclosure policy

Share RecommendKeepReplyMark as Last Read

From: Lynn6/4/2018 9:25:27 PM
1 Recommendation   of 147
I am doing a copy/paste of the entire article in IBD, not just the section on ABMD, in case other stocks held by the mutual fund are of interest to others (AMZN, NFLX, BABA). For anyone just interested in ABMD, though, I am copying it before the entire article:

"Abiomed is in the dynamic growth bucket. The stock replaced leisure-lodging stock Wyndham Worldwide ( WYN) in the S&P 500 index. Many funds, especially index funds, will add Abiomed to their portfolios just because it is now part of the popular benchmark. "Abiomed has had the biggest innovation in cardiac surgery in years by having a balloon pump to help patients extend the life of their hearts during cardiac arrest," lead manager Kelly said. "It works substantially better than all preceding technologies."

The company's market opportunity is about 10 times what its market is today, Kelly says, as its technology grabs market share over the next five to 10 years."

Growth Stocks Like Abiomed And Alibaba Drive This MainStay Fund's Outperformance

  • 6/01/2018
    How hot is $12.5 billion MainStay Large Cap Growth Fund (MLAAX) right now? Very! Driven by leading growth stocks like Abiomed ( ABMD), Alibaba ( BABA), ( AMZN) and Netflix ( NFLX), the MainStay fund is up 13.37% this year going into Thursday.

    That tops 95% of rival large-cap funds focused on growth stocks that are tracked by Morningstar. And it dwarfs the S&P 500's 2.7%.

    Abiomed, which was added to the S&P 500 on Thursday, has grown earnings per share at a triple-digit pace in the past three quarters. The maker of cardiac pumping devices is up 103% so far this year.

    As of Thursday, Alibaba was up 15% this year. Amazon had climbed 39%. Netflix had notched an 83% gain.

    As the fund explains to investors considering buying shares, the managers look "to diversify holdings across three distinct, yet complementary, types of earnings growth to participate in different market cycles."

    In addition, the fund sticks to subadvisor Winslow Capital's "no preferred habitat" approach. That means broad diversification with an eye to managing risk by not being overexposed to any one area of the market.

    MainStay fund managers Justin Kelly and Patrick Burton cope with different market environments by adjusting their allocations among three types, or buckets, of growth stocks.

    One bucket holds stocks that Kelly and Burton think will be able to sustain earnings growth for long periods. The second bucket holds dynamic growth stocks — stocks in newer industries with rapid growth. The third bucket holds cyclical growth stocks. Operating in more economically sensitive sectors, they may be more volatile.

    Leading Growth Stocks Abiomed is in the dynamic growth bucket. The stock replaced leisure-lodging stock Wyndham Worldwide ( WYN) in the S&P 500 index. Many funds, especially index funds, will add Abiomed to their portfolios just because it is now part of the popular benchmark.

    "Abiomed has had the biggest innovation in cardiac surgery in years by having a balloon pump to help patients extend the life of their hearts during cardiac arrest," lead manager Kelly said. "It works substantially better than all preceding technologies."

    The company's market opportunity is about 10 times what its market is today, Kelly says, as its technology grabs market share over the next five to 10 years.

    Alibaba's Four Markets Alibaba is another dynamic growth holding. It is the leading e-commerce platform in China, and its share is growing.

    "Alibaba is pursuing four markets that are extremely large," Burton said. "The first is its traditional e-commerce business in China. The second is digital advertising. As the company adds e-commerce customers, it boosts its advertising business. The third is its cloud computing business. As it builds its online infrastructure, it can sell that service to other companies. And the fourth is its emerging retail business. It is taking its e-commerce and logistics expertise and applying them to grocery and food delivery, where there is a massive total available market opportunity."

    Alibaba is a member of the IBD 50 roster of growth stocks. So are Netflix and Abiomed.

    Amazon, which is on IBD's Leaderboard, is in the fund's consistent growers bucket. The stock barely paused when it recently took heat amid news that one of the company's Echo smart-speaker devices recorded a couple's private conversation in their home and sent it to someone on their contact list without their knowledge.

    "Amazon is our largest holding," Kelly said. "We're still excited about their two main businesses. The first is retail, which still has a tremendous runway to go. They have 5% of total retail transactions in the U.S., but they get 20% of the total growth. That indicates that they will get to 20% of the total market, so the opportunity is four times what it is today."

    Amazon Web Services is the second business that Kelly and Burton like. "We think it is in the early stages of moving corporate work flows from on-premises software to the cloud. Their technology for doing this is in the front of the industry, so they should remain the leader, with Microsoft ( MSFT) number two, and that's why Microsoft is our second largest holding."

    Other Growth Stocks Among other holdings, ASML ( ASML) is in the fund's cyclical growth bucket. The Dutch-based company is a manufacturer of lithography systems used to manufacture integrated circuits. Its shares are up 15% this year.

    "ASML has two key drivers," Burton said. "First is global demand for semiconductor chips, which is expanding at two-plus times the growth rate of global GDP. It's driven by growth in cloud computing and mobile communications."

    Burton likes ASML's EUV technology. "It stands for extreme ultraviolet, and it helps makers of chips. ASML is the only company in the world with this technology."
    [huge chart for fund cut out--see article via link if interested in the mutual fund]

    Share RecommendKeepReplyMark as Last Read

    From: Lynn6/7/2018 2:09:09 PM
       of 147
    I shall post the entire article after this, but the article says some fund managers are going with ABMD (and BABA) because they are better values than AMZN.

    "Some fund managers are avoiding Amazon as it leads U.S. market"
    7 June 2018

    NEW YORK (Reuters) - For most U.S. fund managers, beating the market this year has come down to one decision: whether or not to own shares of Inc ( AMZN.O).

    More than 70 percent of the actively-managed U.S. large-cap funds that are beating the 3.5-percent gain in the benchmark S&P 500 own shares of the Seattle-based e-commerce giant, according to Lipper data. Shares of the company are up nearly 45 percent for the year-to-date, and account for nearly 40 percent of the S&P 500’s gain for the year, according to S&P Global.

    Those gains have left even investors like Warren Buffett, who has never invested in Amazon, kicking themselves for missing out on the company’s growth.

    “I was too dumb to realize what was going to happen,” Buffett said at Berkshire Hathaway Inc’s ( BRKa.N) annual shareholder meeting in early May.

    Amazon has benefited this year from continued growth of e-commerce and is a business that seems largely immune from the threat of a global trade wars.

    Yet with volatility in the stock market expected to continue through the U.S. midterm elections in the fall, Amazon’s pricy valuation and high level of fund ownership may leave the stock more vulnerable to a steep decline, analysts warn.

    As a result, some outperforming fund managers who have so far avoided Amazon are branching out into companies ranging from Asian e-commerce company Alibaba Group Holdings Ltd ( BABA.N) to medical device maker Abiomed Inc ( ABMD.O), all in an effort to find better values.

    “Not owning Amazon has obviously hurt us this year, but we’ve been fortunate to own names that have made up the difference,” said Bob Doll, portfolio manager of the Nuveen Growth fund.

    Doll has avoided Amazon because of its trailing price-to-earnings ratio of 267, a valuation more than ten times that of the broad S&P 500. Instead, he has benefited from positions in MasterCard Inc ( MA.N), Red Hat Inc ( RHT.N), and Intuit Inc ( INTU.O), all of which are up more than 30 percent for the year and trade at less than a third of Amazon’s valuation.

    “These stocks aren’t exactly cheap, they’re cheap compared to a concept stock like Amazon where the valuation is so full,” he said. Inc1683.8



    Scott Goginsky, a portfolio manager at the Biondo Growth Fund, said that his fund has been increasing its position in Alibaba instead of owning Amazon because he sees it as a cheaper way to invest in the growth of e-commerce.

    “Would we have liked to be in Amazon 5 years ago? Yes. But in last year maybe Alibaba is the way to play it, because you’re getting the same growth profile without the same multiple.”

    Shares of Alibaba are up 21 percent for the year and trade at a trailing price to earnings ratio of 54.3.

    Fund manager concentration in Amazon may leave the company more vulnerable to sell off if the volatility in the broad market increases this fall ahead of the mid-term elections, said Todd Rosenbluth, director of mutual fund research at CFRA Research.

    “We’re of the belief that there will be greater market volatility for the duration of 2018 and while in theory that gives active managers a chance to buy in on whatever they have missed out on, that volatility could hit the better performers first,” he said.

    The outsized gain in Amazon relative to other stocks in the S&P 500 suggests that growth is hard to come by in the U.S. market and should benefit more concentrated portfolios, said Daniel Davidowitz, a portfolio manager of the $2.1-billion Polen Growth Fund.

    Davidowitz, whose fund holds only 20 stocks, said he has avoided Amazon because of its high valuation and stretched balance sheet and has instead moved into stocks like Invisalign braces-maker Align Technology Inc ( ALGN.O) and Adobe Systems Inc ( ADBE.O), both of which are up more than 40 percent year-to-date.

    “The average U.S. company is not growing that much. Earnings may be up a lot but a big slug of that is from the benefits of the Trump tax cut,” he said. “The only way to outperform is to find companies that are creating their own theme.”

    Reporting by David Randall; Editing by Jennifer Ablan and Nick Zieminski

    Share RecommendKeepReplyMark as Last Read

    From: Lynn6/26/2018 2:13:42 PM
       of 147
    Call it wishful thinking, but I think the ABMD BOD has a 2:1 stock split in mind due to a proposal on the annual meeting [8 August] voting Proxy I just received (e-mail) to increase the shares:

    "Amend and restate the ABIOMED, Inc. Amended and Restated 2015 Omnibus Incentive Plan to, among other things, increase the number of shares of common stock available for the issuance thereunder by 1,725,000 shares to 4,985,000 shares"

    Share RecommendKeepReplyMark as Last Read

    From: Lynn7/2/2018 2:47:11 PM
    1 Recommendation   of 147
    Newbie Abiomed edges out Netflix as S&P 500’s top YTD gainer

    Jessica Dye in New York
    Financial Times
    June 29, 2018

    Abiomed — which was moved from the S&P MidCap 400 to replace Wyndham Worldwide in the benchmark S&P 500 starting May 31 — has risen 120 per cent in the first six months of the year, according to Thomson Reuters data. Among analysts, Abiomed has five “strong buy” ratings, four “buy”, two “hold” and no sells, with a mean price target of $418.33, according to Thomson Reuters data.

    [One has to subscribe to read the rest of the article]

    Share RecommendKeepReplyMark as Last Read
    Previous 10 Next 10